Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Artelo biosciences, inc. symbols : AZN save search
Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business UpdateMajor achievements in 2023 lay the foundation for key upcoming milestones
Published: 2024-03-25 (Crawled : 16:00) - biospace.com/
AZNCF | $140.15 560
|
Health Technology
|
| O: 0.75%
H: 0.04%
C: -0.1%
AZN | $68.635 0.15% 1.3M
|
Health Technology
|
| O: -0.08%
H: 0.33%
C: -0.53%
ARTL | $1.29 -1.9% 12K
|
Health Technology
|
| O: -4.61%
H: 4.83%
C: 3.84%
business lay key financial results foundation
Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update
Published: 2024-03-25 (Crawled : 12:00) - globenewswire.com
AZNCF | $140.15 560
|
Health Technology
|
| O: 0.75%
H: 0.04%
C: -0.1%
AZN | $68.635 0.15% 1.3M
|
Health Technology
|
| O: -0.08%
H: 0.33%
C: -0.53%
ARTL | $1.29 -1.9% 12K
|
Health Technology
|
| O: -4.61%
H: 4.83%
C: 3.84%
business update financial results
Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain Cancers
Published: 2023-11-09 (Crawled : 14:00) - globenewswire.com
AZNCF | $140.15 560
|
Health Technology
|
| O: 2.33%
H: 0.83%
C: -0.88%
AZN | $68.635 0.15% 1.3M
|
Health Technology
|
| O: 2.72%
H: 0.49%
C: -1.79%
ARTL | $1.29 -1.9% 12K
|
Health Technology
|
| O: 3.47%
H: 0.0%
C: -11.41%
art27 art27.13 publication research
Principal Investigator of Artelo’s CAReS Trial to Participate in Medical Expert Webinar Hosted by H.C. Wainwright to Discuss Current Development Strategies for Cancer-Related Anorexia and Cachexia
Published: 2023-10-04 (Crawled : 13:00) - globenewswire.com
AZNCF | $140.15 560
|
Health Technology
|
| O: 0.92%
H: 0.0%
C: 0.0%
AZN | $68.635 0.15% 1.3M
|
Health Technology
|
| O: 0.42%
H: 0.3%
C: 0.12%
ARTL | $1.29 -1.9% 12K
|
Health Technology
|
| O: 5.84%
H: 0.0%
C: -3.45%
cares medical trial
Artelo Biosciences Initiates the Phase 2a Portion of its CAReS Trial EvaluatingART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
Published: 2023-04-25 (Crawled : 13:00) - biospace.com/
AZNCF | $140.15 560
|
Health Technology
|
| O: -2.02%
H: 0.67%
C: 0.67%
AZN | $68.635 0.15% 1.3M
|
Health Technology
|
| O: 0.91%
H: 0.08%
C: -1.1%
ARTL | $1.29 -1.9% 12K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -21.75%
art27 treatment cares trial
Artelo Biosciences Reports Fiscal 2022 Year-End Financial Results and Provides Business Update
Published: 2023-03-31 (Crawled : 12:20) - globenewswire.com
AZNCF | $140.15 560
|
Health Technology
|
| O: 0.62%
H: 0.0%
C: 0.0%
AZN | $68.635 0.15% 1.3M
|
Health Technology
|
| O: 0.98%
H: 0.07%
C: -0.67%
ARTL | $1.29 -1.9% 12K
|
Health Technology
|
| O: -3.26%
H: 12.98%
C: 11.54%
business update financial results
Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight LossExpects to Commence Phase 2a of CAReS During the First Quarter of 2023
Published: 2023-02-02 (Crawled : 15:20) - biospace.com/
AZNCF | $140.15 560
|
Health Technology
|
| O: -2.3%
H: 2.11%
C: 1.78%
AZN | $68.635 0.15% 1.3M
|
Health Technology
|
| O: -0.31%
H: 0.05%
C: -0.33%
ARTL | $1.29 -1.9% 12K
|
Health Technology
|
| O: -1.27%
H: 1.67%
C: -0.96%
art27 treatment cares trial art27.13 phase 2b
Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
Published: 2023-02-02 (Crawled : 14:20) - globenewswire.com
AZNCF | $140.15 560
|
Health Technology
|
| O: -2.3%
H: 2.11%
C: 1.78%
AZN | $68.635 0.15% 1.3M
|
Health Technology
|
| O: -0.31%
H: 0.05%
C: -0.33%
ARTL | $1.29 -1.9% 12K
|
Health Technology
|
| O: -1.27%
H: 1.67%
C: -0.96%
art27 treatment cares trial art27.13 phase 2b
Artelo Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
Published: 2022-11-08 (Crawled : 14:00) - biospace.com/
AZNCF | $140.15 560
|
Health Technology
|
| O: 2.49%
H: 0.0%
C: -1.6%
AZN | $68.635 0.15% 1.3M
|
Health Technology
|
| O: 0.2%
H: 0.96%
C: 0.18%
ARTL | $1.29 -1.9% 12K
|
Health Technology
|
| O: 0.0%
H: 4.74%
C: 4.74%
financial update results
Artelo Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
Published: 2022-08-09 (Crawled : 12:20) - globenewswire.com
AZNCF | $140.15 560
|
Health Technology
|
| O: -3.88%
H: 0.0%
C: 0.0%
AZN | $68.635 0.15% 1.3M
|
Health Technology
|
| O: 1.23%
H: 0.77%
C: -0.05%
ARTL | $1.29 -1.9% 12K
|
Health Technology
|
| O: -8.28%
H: 2.62%
C: -16.76%
update results
Artelo Biosciences Completes Enrollment of the First Three Cohorts in its CAReS Study Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
Published: 2022-07-19 (Crawled : 13:20) - globenewswire.com
AZNCF | $140.15 560
|
Health Technology
|
| O: -0.67%
H: 1.97%
C: 1.17%
AZN | $68.635 0.15% 1.3M
|
Health Technology
|
| O: 2.23%
H: 0.8%
C: 0.46%
ARTL | $1.29 -1.9% 12K
|
Health Technology
|
| O: 0.0%
H: 6.99%
C: 1.61%
art27 treatment art27.13 study
Artelo Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update
Published: 2022-05-12 (Crawled : 13:00) - biospace.com/
AZNCF | $140.15 560
|
Health Technology
|
| O: -2.2%
H: 3.27%
C: 0.6%
AZN | $68.635 0.15% 1.3M
|
Health Technology
|
| O: -2.18%
H: 1.85%
C: 1.55%
ARTL | $1.29 -1.9% 12K
|
Health Technology
|
| O: 2.97%
H: 5.13%
C: 4.59%
results
Artelo Biosciences Reports Positive Pre-clinical Results for Lead Program in Cancer-Related Cachexia
Published: 2022-04-13 (Crawled : 13:00) - biospace.com/
AZNCF | $140.15 560
|
Health Technology
|
| O: -3.19%
H: 3.22%
C: 0.54%
AZN | $68.635 0.15% 1.3M
|
Health Technology
|
| O: -0.04%
H: 0.84%
C: 0.57%
ARTL | $1.29 -1.9% 12K
|
Health Technology
|
| O: 38.1%
H: 27.29%
C: -12.83%
pre-clinical program positive art27.13 preclinical cancer
Artelo Biosciences Reports Four-Month 2021 Financial Results in Connection with its Amended Fiscal Year End and Provides Business Update
Published: 2022-03-21 (Crawled : 16:00) - biospace.com/
AZNCF | $140.15 560
|
Health Technology
|
| O: 0.0%
H: 0.06%
C: -4.79%
AZN | $68.635 0.15% 1.3M
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
ARTL | $1.29 -1.9% 12K
|
Health Technology
|
| O: 6.58%
H: 5.0%
C: 0.65%
results
Artelo Biosciences Reports First Quarter Fiscal Year 2022 Financial Results and Provides Business Update
Published: 2022-01-12 (Crawled : 14:00) - globenewswire.com
AZNCF | $140.15 560
|
Health Technology
|
| O: 0.0%
H: 0.76%
C: -0.16%
AZN | $68.635 0.15% 1.3M
|
Health Technology
|
| O: 1.68%
H: 0.0%
C: 0.0%
ARTL | $1.29 -1.9% 12K
|
Health Technology
|
| O: 0.28%
H: 2.47%
C: 1.13%
bioscience
Artelo Biosciences Reports Fiscal 2021 Year-End Financial Results and Provides Business Update
Published: 2021-11-29 (Crawled : 17:00) - globenewswire.com
AZNCF | $140.15 560
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: 0.0%
AZN | $68.635 0.15% 1.3M
|
Health Technology
|
| O: -1.57%
H: 0.0%
C: 0.0%
ARTL | $1.29 -1.9% 12K
|
Health Technology
|
| O: 5.5%
H: 0.0%
C: -11.8%
financial results bioscience results
Artelo Biosciences Doses First Patient in CAReS Study with ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
Published: 2021-04-12 (Crawled : 13:00) - globenewswire.com
AZN | $68.635 0.15% 1.3M
|
Health Technology
|
| O: -0.22%
H: 0.18%
C: -0.82%
ARTL | $1.29 -1.9% 12K
|
Health Technology
|
| O: -0.66%
H: 1.99%
C: -8.61%
weight loss treatment cancer art27.13
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
AGBA | $0.7995 99.88% 73M
|
Finance
BPTH | $6.21 91.67% 58M
|
Health Technology
INVO | $1.36 78.95% 3.6M
|
Health Technology
TIRX | $0.8231 69.78% 54M
|
ISPC | $0.307 44.13% 3.6M
|
Professional, Scientific, and T...
SINT | $0.0519 39.14% 350M
|
Health Technology
XPON | $2.63 36.27% 8.4M
|
ALRN | $5.53 30.12% 250K
|
Health Technology
VTNR S | $1.26 28.68% 9.1M
|
Industrial Services
HOLO | $2.86 27.68% 28M
|
Your saved searches
Save your searches and get alerts when important news are released.